Blood-brain barrier structure and function and the challenges for CNS drug delivery - PubMed (original) (raw)
Review
Blood-brain barrier structure and function and the challenges for CNS drug delivery
N Joan Abbott. J Inherit Metab Dis. 2013 May.
Abstract
The neurons of the central nervous system (CNS) require precise control of their bathing microenvironment for optimal function, and an important element in this control is the blood-brain barrier (BBB). The BBB is formed by the endothelial cells lining the brain microvessels, under the inductive influence of neighbouring cell types within the 'neurovascular unit' (NVU) including astrocytes and pericytes. The endothelium forms the major interface between the blood and the CNS, and by a combination of low passive permeability and presence of specific transport systems, enzymes and receptors regulates molecular and cellular traffic across the barrier layer. A number of methods and models are available for examining BBB permeation in vivo and in vitro, and can give valuable information on the mechanisms by which therapeutic agents and constructs permeate, ways to optimize permeation, and implications for drug discovery, delivery and toxicity. For treating lysosomal storage diseases (LSDs), models can be included that mimic aspects of the disease, including genetically-modified animals, and in vitro models can be used to examine the effects of cells of the NVU on the BBB under pathological conditions. For testing CNS drug delivery, several in vitro models now provide reliable prediction of penetration of drugs including large molecules and artificial constructs with promising potential in treating LSDs. For many of these diseases it is still not clear how best to deliver appropriate drugs to the CNS, and a concerted approach using a variety of models and methods can give critical insights and indicate practical solutions.
Similar articles
- In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.
Bagchi S, Chhibber T, Lahooti B, Verma A, Borse V, Jayant RD. Bagchi S, et al. Drug Des Devel Ther. 2019 Oct 18;13:3591-3605. doi: 10.2147/DDDT.S218708. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31695329 Free PMC article. Review. - Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ. Begley DJ. Pharmacol Ther. 2004 Oct;104(1):29-45. doi: 10.1016/j.pharmthera.2004.08.001. Pharmacol Ther. 2004. PMID: 15500907 Review. - From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
Soddu E, Rassu G, Giunchedi P, Sarmento B, Gavini E. Soddu E, et al. Eur J Pharm Sci. 2015 Jul 10;74:63-76. doi: 10.1016/j.ejps.2015.04.005. Epub 2015 Apr 16. Eur J Pharm Sci. 2015. PMID: 25892455 Review. - Targetability of the neurovascular unit in inflammatory diseases of the central nervous system.
Smith BC, Tinkey RA, Shaw BC, Williams JL. Smith BC, et al. Immunol Rev. 2022 Oct;311(1):39-49. doi: 10.1111/imr.13121. Epub 2022 Jul 31. Immunol Rev. 2022. PMID: 35909222 Free PMC article. Review.
Cited by
- CAR T Cell Therapy for Pediatric Brain Tumors.
Patterson JD, Henson JC, Breese RO, Bielamowicz KJ, Rodriguez A. Patterson JD, et al. Front Oncol. 2020 Aug 12;10:1582. doi: 10.3389/fonc.2020.01582. eCollection 2020. Front Oncol. 2020. PMID: 32903405 Free PMC article. Review. - Epigenetic Regulation of Ferroportin in Primary Cultures of the Rat Blood-Brain Barrier.
Helgudottir SS, Routhe LJ, Burkhart A, Jønsson K, Pedersen IS, Lichota J, Moos T. Helgudottir SS, et al. Mol Neurobiol. 2020 Aug;57(8):3526-3539. doi: 10.1007/s12035-020-01953-y. Epub 2020 Jun 15. Mol Neurobiol. 2020. PMID: 32542592 - Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression.
He X, Zhu Y, Wang M, Jing G, Zhu R, Wang S. He X, et al. Int J Nanomedicine. 2016 Oct 3;11:4975-4990. doi: 10.2147/IJN.S109088. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27757031 Free PMC article. - Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma.
Kim J, Dey A, Malhotra A, Liu J, Ahn SI, Sei YJ, Kenney AM, MacDonald TJ, Kim Y. Kim J, et al. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24205-24212. doi: 10.1073/pnas.1911229117. Epub 2020 Sep 15. Proc Natl Acad Sci U S A. 2020. PMID: 32934143 Free PMC article. - Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications.
Ortiz R, Perazzoli G, Cabeza L, Jiménez-Luna C, Luque R, Prados J, Melguizo C. Ortiz R, et al. Curr Neuropharmacol. 2021;19(4):513-537. doi: 10.2174/1570159X18666200626204005. Curr Neuropharmacol. 2021. PMID: 32589560 Free PMC article. Review.
References
- Nat Rev Mol Cell Biol. 2007 Aug;8(8):603-12 - PubMed
- Trends Neurosci. 2005 Apr;28(4):202-8 - PubMed
- Mol Cell Biol. 2012 Sep;32(17):3414-27 - PubMed
- Curr Drug Metab. 2008 Nov;9(9):901-10 - PubMed
- Mol Genet Metab. 2010 Oct-Nov;101(2-3):208-13 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources